BCM
XENT

Bayesian Capital Management’s Intersect ENT, Inc XENT Stock Holding History

Bayesian Capital Management’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-8,575
Closed -$267K – 772
2017
Q3 		$267K Buy
+8,575
New +$254K 0.06% 391
2017
Q1 		– Sell
-12,465
Closed -$151K – 754
2016
Q4 		$151K Buy
+12,465
New +$161K 0.04% 549

Other funds holding XENT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bayesian Capital Management's XENT Position: Q4 2017 in Review

Bayesian Capital Management sold out of Intersect ENT, Inc (XENT) in Q4 2017, closing a stake of 8,575 shares — an estimated $267K sold.

Bayesian Capital Management first reported a position in XENT in Q4 2016 and held it in 2 quarters. The position peaked at $267K in Q3 2017. 157 funds tracked by Wall St. Rank hold XENT as of Q4 2017.

  • Bayesian Capital Management reported no remaining Intersect ENT, Inc position as of Q4 2017 after selling out during the quarter.
  • Bayesian Capital Management sold 8,575 Intersect ENT, Inc shares in Q4 2017, an estimated $267K.
  • Bayesian Capital Management first reported a position in Intersect ENT, Inc in Q4 2016 and held it in 2 quarters.
  • Bayesian Capital Management's Intersect ENT, Inc position peaked at $267K in Q3 2017.
  • 157 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q4 2017.

Based on Bayesian Capital Management's 13F filing for Q4 2017, filed 12 Feb 2018.